Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts.
A mouse monoclonal anti-CEA antibody (11.285.14) has been examined for tumour localization potential by assessing its distribution in immunodeprived mice with xenografts of human colon carcinoma cell lines HCT-8, HRT-18, HT-29, and LS174T and a xenograft (HRVB) established from a primary rectal carcinoma. With four carcinomas (HCT-8, HT-29, LS174T, and HRVB) preferential tumour localization of 125I anti-CEA was seen. Compared with 131I normal IgG1 localization indices of up to 4.4:1 were achieved. Up to 10% of the injected dose of 125I anti-CEA was present/g of tumour tissue and with the largest xenografts examined (3-4 g) up to 40% of the total body reactivity was localized in tumour tissue. The tumour localization of 131I labelled antibody was visualized by external gamma camera imaging. Overall antibody localization correlated with the CEA content of the xenografts and the fourth colon carcinoma xenograft (HRT-18) and an osteogenic sarcoma xenograft (791T), both with very low CEA levels, showed no localization of the monoclonal antibody.
D000818:Animals; D000911:Antibodies, Monoclonal; D001345:Autoradiography; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology; D006801:Humans; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D012004:Rectal Neoplasms / Q000276:immunology
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen